Lengthening of QT interval by antipsychotic drugs;Antipsychotikainduzierte QT-verlängerung

Nervenarzt

Volumn 77, Issue 3, 2006, Pages 276-288

  Haverkamp, W ^a   Deuschle, M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Arrhythmias; Haloperidol; Neuroleptics; QT interval; Sertindole; Sudden death; Thioridazine; Torsade de pointes; Ziprasidone

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SOTALOL; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE;

DISEASE PREDISPOSITION; DRUG EXCRETION; DRUG METABOLISM; DRUG OVERDOSE; ELECTROCARDIOGRAM; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; INTOXICATION; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

ANTIPSYCHOTIC AGENTS; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; RISK FACTORS; SCHIZOPHRENIA; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES;

EID: 33645219292     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-005-1966-x     Document Type: Review

References (53)

1. Haverkamp W, Breithardt G, Camm AJ et al. (2000) The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47:219-233
2. Appleby L, Thomas S, Ferrier N et al. (2000) Sudden unexplained death in psychiatric in-patients. Br J Psychiatry 176:405-406
3. Malik M (2001) Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12:411-420
4. Davey P (2002) How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods 48:3-9
5. Hodges M (1997) Rate correction of the QT interval. Card Electrophysiol Rev 3:360-363
6. Roden DM (1993) Torsade de pointes. Clin Cardiol 16:683-686
7. Haverkamp W, Hördt M, Chen X et al. (1993) Torsade de pointes. Z Kardiol 82:763-774
8. Haverkamp W, Mönnig G, Schulze-Bahr E et al. (2002) Physician-induced torsade de pointes-therapeutic implications. Cardiovasc Drugs Ther 16:101-109
9. Antzelevitch C, Nesterenko VV, Yan GX (1995) Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. J Electrocardiol 28:131-138
10. Sicouri S, Antzelevitch C (1990) Drug-induced early and delayed afterdepolarizations and triggered activity in deep subepicardial celles (M cells) of the canine ventricle. Circulation 82:III-645
11. Roden DM (1998) Taking the "idio" out of " idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21:1029-1034
12. Roden DM, Lazzara R, Rosen M et al. (1996) Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 94:1996-2012
13. Buckley NA, Whyte IM, Dawson AH (1995) Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 33:199-204
14. Suessbrich H, Schonherr R, Heinemann SH et al. (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 120:968-974
15. Fulop G, Phillips RA, Shapiro AK et al. (1987) ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 144:673-675
16. Harrigan EP, Miceli JJ, Anziano R et al. (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24:62-69
17. Sharma ND, Rosman HS, Padhi ID et al. (1998) Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 81:238-240
18. Wilt JL, Minnema AM, Johnson RF et al. (1993) Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 119:391-394
19. Hunt N, Stern TA (1995) The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. Psychosomatics 36:541-549
20. Osypenko VM, Degtiar VI, Naid'onov VG et al. (2001) Blockade of HERG K+ channels expressed in Xenopus oocytes by antipsychotic agents. Fiziol Zh 47:17-25
21. Committee on Safety of Medicines-Medicines Control Agency (1995) Cardiac arrhythmias with pimozide (Orap). Current Problems in Pharmacolovigilance
22. Kelly HG, Fay JE, Laverty SG et al. (1963) Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report on two fatalities with electrocardiographic abnormalities. Can Med Assoc J 89:546-554
23. Peele R, Von Loetzen IS (1973) Phenothiazine deaths: a critical review. Am J Psychiatry 130:306-309
24. Donatini B, Le BI, Krupp P (1992) Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine. Cardiology 81:340-341
25. Drolet B, Vincent F, Rail J et al. (1999) Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288:1261-1268
26. Witchel HJ, Hancox JC, Nutt DJ (2003) Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 23:58-77
27. Warner B, Hoffmann P (2002) Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 21:189-203
28. Drici MD, Wang WX, Liu XK et al. (1998) Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18:477-481
29. Tie H, Walker BD, Singleton CB et al. (2001) Clozapine and sudden death. J Clin Psychopharmacol 21:630-632
30. Johal BK, Shelly MP (2000) Olanzapine overdose. Anaesthesia 55:929
31. Gluais P, Bastide M, Caron J et al. (2002) Risperidone prolongs cardiac action potential through reduction of K+ currents in rabbit myocytes. Eur J Pharmacol 444:123-132
32. Zimbroff DL, Kane JM, Tamminga CA et al. (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schoziphrenia. Am J Psychiatry 154:782-791
33. Moore N, Hall G, Sturkenboom M et al. (2003) Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 12:271-281
34. Eckardt L, Breithardt G, Haverkamp W (2002) Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 300:64-71
35. Beelen AP, Yeo KT, Lewis LD (2001) Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 20:215-219
36. Gajwani P, Pozuelo L, Tesar GE (2000) QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 41:63-65
37. Furst BA, Champion KM, Pierre JM et al. (2002) Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry 51:264-265
38. Kongsamut S, Kang J, Chen XL et al. (2002) A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 450:37-41
39. Haverkamp W, Naber D, Maier W et al. (2003) Elektrokardiographische Effekte und kardiale Siocherheit von Ziprasidon: Ergebnisse der ZEISIG-Studie (Ziprasidone experience in schizophrenia in Germany/Austria). Nervenarzt 74(Suppl 2):178
40. Burton S, Heslop K, Harrison K et al. (2000) Ziprasidone overdose. Am J Psychiatry 157:835
41. Biswas AK, Zabrocki LA, Mayes KL et al. (2003) Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol 41:101-104
42. Lande G, Drouin E, Gauthier C et al. (1992) Arrhythmogenic effects of sultopride chlorhydrate: clinical and cellular electrophysiological correlation. Ann Fr Anesth Reanim 11:629-635
43. Adamantidis MM, Kerram P, Dupuis BA (1994) In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 8:391-407
44. Tracqui A, Mutter SC, Kintz P et al. (1995) Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 14:294-298
45. Hamon-Vilcot B, Chaufour S, Deschamps C et al. (1998) Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. Eur J Clin Pharmacol 54:405-409
46. Agelink MW, Majewski T, Wuthmann C et al. (2001) Effects of newer antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole and clozapine. J Clin Psychopharmacol 21:8-13
47. Bont L, Bosker HA, Brus F et al. (1998) Torsade de pointes after pipamperone intoxication. Pharm World Sci 20:137
48. Iglesias E, Esteban E, Zabala S et al. (2000) Tiapride-induced torsade de pointes. Am J Med 109:509
49. Swainston Harrison T, Perry CM (2004) Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64:1715-1736
50. Reilly JG, Ferrier IN, Jones SJ et al. (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048-1052
51. Jackson T, Ditmanson L, Phibbs B (1997) Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 157:2013-2015
52. Sachdev P (2001) The prolongation of QTc-interval by thioridazine. Aust NZ J Psychiatry 35:857-858
53. Glassman AH, Bigger JT (2001) Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes and sudden death. Am J Psychiatry 158:1774-1782